Published • loading... • Updated
Axsome: Q3 Earnings Snapshot – WTOP News
Revenue rose 52% as AUVELITY demand accelerated and the company beat Wall Street estimates on both sales and earnings.
- On November 4, 2026, molecular diagnostics company BillionToOne reported Q3 2026 revenue of $123 million, a 47% increase year-over-year, alongside a $492 million annualized revenue run rate.
- Revenue growth stemmed from a 25% surge in test volume to 206,000 tests, complemented by an 18% increase in average selling price.
- Oncology segment revenue nearly doubled to $17.1 million, while the prenatal segment reported $105.9 million in revenue, a 42% increase.
- Profitability metrics for the quarter included $17.4 million in net income and $22.7 million in adjusted EBITDA, supported by $562 million cash.
- The company plans to launch Northstar Clear, a pan-cancer tissue-free MRD test, on December 15, 2026, targeting a portion of the estimated $30 billion annual market.
Insights by Ground AI
228 Articles
228 Articles
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Mattel Cuts Annual Forecasts as New CEO Roger Lynch Takes Charge
Mattel lowered its full-year sales and profit forecasts on Thursday ahead of the critical holiday shopping season, placing new CEO Roger Lynch under pressure to ... The post Mattel Cuts Annual Forecasts as New CEO Roger Lynch Takes Charge first appeared on [your]NEWS.
Coverage Details
Total News Sources228
Leaning Left31Leaning Right20Center60Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 28%
C 54%
R 18%
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
